

# Proteomics International

LABORATORIES LTD

ASX Release  
19 February 2018

ASX code: PIQ

## Expiry of PIQO Options Notice to Option Holders

Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) advises that the letters following this announcement were sent to holders of listed options exercisable at \$0.20 per option on or before 31 March 2018 (ASX: PIQO), as notification of the expiry of their options on 31 March 2018.

The last date of quotation of the PIQO options on the ASX will be 23 March 2018.

The PIQO Options are currently in the money with the PIQO Shares having closed at \$0.29 on 16 February 2018.

Any other questions concerning the exercise of PIQO Options may be directed to the Company by email at [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com).

ENDS

### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Karen Logan  
Company Secretary  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

### About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. Proteomics International is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)



# Proteomics International

LABORATORIES LTD

19 February 2018

Dear Option Holder,

Accompanying this letter is a formal advice showing your holding of **PIQO** options, and the courses of action available to you as the holder of those options. **This is an important document and should be carefully considered** – you may wish to take advice from your financial advisor, accountant or other professional.

Proteomics International Laboratories Ltd (Proteomics International, the Company; ASX: **PIQ**) listed on the ASX in 2015, and since then has achieved significant development focused on its diagnostics and analytics operations. The Board believes the Company is now strongly positioned for revenue growth.

The landmark achievement has been the development of the world leading predictive diagnostic test for diabetic kidney disease, PromarkerD. This has since been validated in clinical studies and last year was published in the leading scientific journal *Diabetes Care*. The first licensing deal for PromarkerD will see the test launched next month in Central America.

These pivotal milestones provide a springboard for further licensing and partnering deals in the year ahead. Patents for PromarkerD have already been granted in the major healthcare markets of USA and Japan, along with China, Russia, Singapore and Australia, and remain pending in other major global jurisdictions.

The Promarker™ discovery platform is also being applied to target other diseases where there is unmet medical need, including endometriosis and asthma. Whilst these projects remain at the R&D stage they represent areas for the potential development of new diagnostic tests.

Analytical services are now provided across a range of specialist areas, from the quality control testing of protein drugs (biosimilars and biologics) and food products such as A2 milk, to analysing drug stability (pharmacokinetic testing) in clinical trials for new drugs in development.


As part of its development Proteomics International has also added significant industry and sector experience to strengthen the Board. These actions all support the Company's growth, and any licensing or royalty payments for PromarkerD will build on existing revenue streams to further enhance future cash flows.

There are currently 16,540,806 Options available to be exercised, with the potential to raise up to \$3.3 million. The Directors, including myself, have indicated the intent to exercise their Options. The Company is also finalising negotiations with potential underwriters to take any shortfall that may arise. These funds will be used to continue to leverage the Promarker™ technology across the integrated areas of analytical services, diagnostics and therapeutics.

The enclosed information provides instructions for the exercise of your options. Please ensure that your application is received no later than **5pm (WST) on 31 March 2018**. Due to Easter it is recommended that you allow plenty of time for postage or that you remit your application monies via BPay and lodge your application via email so that it reaches the share registry by this expiry date.

Should you decide to exercise your PIQO options, we welcome you as a shareholder of Proteomics International – we see exciting times ahead for our Company.

Yours sincerely


  
Terry Sweet  
Chairman

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008 Broadway, Nedlands, Perth WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [proteomicsinternational.com](http://proteomicsinternational.com)



# Proteomics International

LABORATORIES LTD

19 February 2018

Dear Option Holder

## OPTIONS EXERCISABLE AT \$0.20 EACH ON OR BEFORE 31 MARCH 2018 (ASX: PIQO)

We write to you as a registered holder of the above number of options in Proteomics International Laboratories Ltd (**Proteomics International** or the **Company**) (ASX: PIQ) as at the date of this notice. The options are exercisable at \$0.20 each, with each option providing the right to purchase a single fully paid ordinary share in Proteomics International.

You are formally advised that these options will expire at 5:00pm (WST) on 31 March 2018. If payment is not received by 5:00pm (WST) on 31 March 2018 the options will lapse and all rights under the options will cease at that time.

The courses of action open to you as a holder of these options are:

- (i) Exercise all or some of the options on or before 31 March 2018.
- (ii) Sell your options. Quotation of the options will cease at the close of trading on 23 March 2018.
- (iii) Do nothing. If you do not take any action to exercise your options prior to 31 March 2018, the options will expire and your rights to subscribe for shares in Proteomics International at \$0.20 will lapse.

There is no obligation on option holders to exercise their options. However, under the ASX Listing Rules, the Company is required to advise option holders of the information contained in this notice.

If you wish to exercise all or part of your options, please complete the attached "Notice of Exercise of Options" and forward it together with payment of \$0.20 per option exercised to be received no later than by 5:00 pm WST on 31 March 2018 by the Company's share registry, being:

**Postal address:**

Security Transfer Registrars Pty Ltd  
PO Box 535,  
Applecross, WA 6953

**Street address:**

Security Transfer Registrars Pty Ltd  
770 Canning Highway,  
Applecross, WA 6153

PIQ shares are currently trading at \$0.29 on 16 February 2018 (being the trading day prior to this notice). The highest and lowest market prices of the shares in the 3 months immediately before this notice are as follows:

Highest	\$0.355	24 January 2018
Lowest	\$0.22	17 and 22 January 2018

If you require further information, please do not hesitate to contact the Company via email at [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com).

Yours sincerely

Karen Logan  
Company Secretary

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

NOTICE OF EXERCISE OF OPTIONS

THIS DOCUMENT IS IMPORTANT. IF YOU ARE IN DOUBT AS TO HOW TO DEAL WITH IT, PLEASE CONTACT YOUR STOCK BROKER OR LICENSED PROFESSIONAL ADVISOR.

**REGISTERED OFFICE:**  
SUITE 13 THE ATRIUM  
123A COLIN STREET  
WEST PERTH WA 6005  
AUSTRALIA

# PROTEOMICS INTERNATIONAL LABORATORIES LTD

ACN: 169 979 971

**SHARE REGISTRY:**  
Security Transfer Australia Pty Ltd

**All Correspondence to:**  
**PO Box 52**  
**Collins Street West VIC 8007**



«Post\_zone»  
«Company\_code» «Sequence\_number»

T: 1300 992 916 F: +61 8 9315 2233  
E: registrar@securitytransfer.com.au  
W: www.securitytransfer.com.au

«Holder\_name»  
«Address\_line\_1»  
«Address\_line\_2»  
«Address\_line\_3»  
«Address\_line\_4»  
«Address\_line\_5»

ASX Code:   
Holder Number:   
Number of Options:   
Amount Payable:

## NOTICE OF EXERCISE OF OPTIONS EXPIRING SATURDAY 31 MARCH 2018 @ \$0.20 EACH

I/We the above named being the registered holder of Options hereby exercise such Options to subscribe for:

### NUMBER OF NEW ORDINARY FULLY PAID SHARES

 ,  , 

### AMOUNT ENCLOSED @ \$0.20 PER SHARE

\$  ,  ,  .

I/We hereby authorise you to place my/our name(s) on the register of members in respect of the number of New Shares allotted to me/us, and I/we agree to accept such Shares subject to the Rules of the Constitution of the Company.

Individual or Securityholder 1

Securityholder 2

Securityholder 3




Sole Director & Company Secretary

Director/Company Secretary

Director

My/Our contact details in case of enquiries are:

**NAME**

**TELEPHONE NUMBER**

(  )

**EMAIL ADDRESS**

### PAYMENT INFORMATION



**Biller code:** 159483

**Ref:** <<EFT\_REFERENCE\_NUMBER>>

**Telephone & Internet Banking – BPAY®**

Contact your bank or financial institution to make this payment from your cheque, savings, debit, or transaction account. More info: www.bpay.com.au

© Registered to BPAY Pty Ltd ABN 69 079 137 518

Applicants should be aware of their financial institution's cut-off time (the time payment must be made to be processed overnight) and ensure payment is processed by their financial institution on or before the day prior to the expiry date. BPAY applications will only be regarded as accepted if payment is received by the registry from your financial institution on or prior to the expiry date. It is the Applicant's responsibility to ensure funds are received by the expiry date.

### CHEQUE / MONEY ORDER

All cheques (expressed in Australian currency) are to be made payable to PROTEOMICS INTERNATIONAL LABORATORIES LTD and crossed "Not Negotiable".

Do not forward cash as receipts will not be issued.

Sufficient cleared funds should be held in your account as your acceptance may be rejected if your cheque is dishonoured.

Cheques or bank drafts drawn on overseas banks in Australian or any foreign currency will NOT be accepted. Any such cheques will be returned and the acceptance deemed to be invalid.

When completed, this form together with the appropriate payment should be forwarded to the share registry.

Your BPAY reference number is unique to these Options and is not to be used for any other offer.  
**BPAY PAYMENT OR THE RETURN OF THIS FORM WITH THE REQUIRED REMITTANCE WILL  
CONSTITUTE YOUR EXERCISING OF THE OPTIONS.**  
**You do not need to return this form if you have made payment via BPAY.**

**REGISTRY DATE STAMP**

E & O.E.

## TERMS AND CONDITIONS OF OPTIONS

a) *Exercise Price*

The exercise price of each Option is \$0.20.

b) *Entitlement*

Each Option shall entitle the holder the right to subscribe (in cash) for one Share in the capital of the Company.

c) *Option Period*

The Options will expire at 5.00pm WST on 31 March 2018 (**Expiry Date**). Subject to clause (g), Options may be exercised at any time prior to the expiry date and Options not so exercised shall automatically lapse on the expiry date.

d) *Ranking of Share Allotted on Exercise of Option*

Each Share allotted as a result of the exercise of any Option will, subject to the Constitution of the Company, rank in all respects pari passu with the existing Shares in the capital of the Company on issue at the date of allotment.

e) *Voting*

A registered owner of an Option (**Option Holder**) will not be entitled to attend or vote at any meeting of the members of the Company unless they are, in addition to being an Option Holder, a member of the Company.

f) *Transfer of an Option*

Options are transferrable at any time prior to the Expiry Date. This right is subject to any restrictions on the transfer of Options that may be imposed by the ASX in circumstances where the Company is listed on the ASX.

g) *Method of Exercise of an Option*

- (i) The Company will provide to each Option Holder a notice that is to be completed when exercising the Options (**Notice of Exercise of Options**). Options may be exercised by the Option Holder by completing the Notice of Exercise of Options and forwarding the same to the Company Secretary to be received prior to the expiry date. The Notice of Exercise of Options must state the number of Options exercised and the consequent number of ordinary shares in the capital of the Company to be allotted; which number of Options must be a multiple of 2,500 if only part of the Option Holder's total Options are exercised, or if the total number of Options held by an Option Holder is less than 2,500, then the total of all Options held by that Option Holder must be exercised.
- (ii) The Notice of Exercise of Options by an Option Holder must be accompanied by payment in full for the relevant number of shares being subscribed, being an amount of \$0.20 per Share.
- (iii) Subject to paragraph (g)(i) above, the exercise of less than all of an Option Holder's Options will not prevent the Option Holder from exercising the whole or any part of the balance of the Option Holder's entitlement under the Option Holder's remaining Options.
- (iv) Within 14 business days from the date the Option Holder properly exercises Options held by the Option Holder, the Company shall issue and allot to the Option Holder that number of Shares in the capital of the Company so subscribed for by the Option Holder.
- (v) If the Company is listed on the ASX, the Company will within 3 business days from the date of issue and allotment of Shares pursuant to the exercise of an Option, apply to the ASX for, and use its best endeavours to obtain, Official Quotation of all such Shares, in accordance with the Corporations Act and the Listing Rules of the ASX.
- (vi) The Company will generally comply with the requirements of the Listing Rules in relation to the timetables imposed when quoted Options are due to expire. Where there shall be any inconsistency between the timetables outlined herein regarding the expiry of the Options and the timetable outlined in the Listing Rules, the timetable outlined in the Listing Rules shall apply.

h) *Reconstruction*

In the event of a reconstruction (including consolidation, sub-division, reduction or return) of the issued capital of the Company, all rights of the Option Holder will be changed to the extent necessary to comply with the Corporations Act and ASX Listing Rules applying to the reconstruction of capital, at the time of the reconstruction.

i) *Participation in New Share Issues*

There are no participating rights or entitlements inherent in the Options to participate in any new issues of capital which may be made or offered by the Company to its shareholders from time to time prior to the expiry date unless and until the Options are exercised. The Company will ensure that during the exercise period, the record date for the purposes of determining entitlements to any new such issue, will be at least five (5) business days after such new issues are announced (or such other date if required under the Listing Rules) in order to afford the Option Holder an opportunity to exercise the Options held by the Option Holder.

j) *No Change of Options' Exercise Price or Number of Underlying Shares*

There are no rights to change the exercise price of the Options or the number of underlying Shares if there is a bonus issue to the holders of ordinary shares. If the Company makes a pro rata issue of securities (except a bonus issue) to the holders of ordinary shares (other than an issue in lieu or in satisfaction of dividends or by way of dividend investment) the Option exercise price shall be reduced according to the formula specified in the Listing Rules.